




Global Health
Supply Chain Summit

ABSTRACT 86
TRACK 6
13 November 2024

LAGOS, NIGERIA ~ NOVEMBER 12-15

2024

VALUE CHAIN INNOVATIONS FOR UNIVERSAL HEALTH COVERAGE



Designing global vaccine stockpiles to achieve public health goals in Africa: Applied to cholera and ebola disease

Donovan Guttieres, Catherine Decouttere, Nico Vandaele

**Access-To-Medicines Research Centre
KU Leuven, Belgium**

Affiliation:

Faculty of Economics & Business
KU Leuven



ACCESS-TO-MEDICINES

Funding support:

Research Chair on
Pandemic Preparedness

**Johnson & Johnson
Innovative Medicine**

Travel support:



Research Foundation -
Flanders




**Global Health
Supply Chain Summit**

donovan.guttieres@kuleuven.be

Access-To-Medicines Research Centre



Outline



Pathogens with epidemic potential

- Priority lists
- Multi-dimensional risks
- Unhealthy vaccine markets

Systems analysis of global vaccine stockpiles


- Approach
- Drivers of behavior
- Case studies

Dynamic understanding of market health

- Conclusions
- Future work



Outline



Pathogens with epidemic potential

- Priority lists
- Multi-dimensional risks
- Unhealthy vaccine markets

Systems analysis of global vaccine stockpiles


- Approach
- Drivers of behavior
- Case studies

Dynamic understanding of market health

- Conclusions
- Future work



Pathogens for which vaccines have been licensed continue to be a high priority for epidemic preparedness



Comparing global and regional (Africa) priorities

- WHO only
- Africa CDC only
- Both WHO & Africa CDC
- WHO pre-qualified vaccines

COVID-19
Crimean-Congo haemorrhagic fever
Ebola Virus Disease
Marburg Virus Disease
Lassa fever
MERS coronavirus & SARS
Nipah and henipaviral diseases
Rift Valley fever
Zika
Cholera
Yellow fever
Meningitis
Measles
Dengue fever
Polio
Rabies
Mpox
Chikungunya
Disease X*





Ranking regional preparedness and response priorities in Africa (2022)

Disease	Risk score	Preparedness score
Ebola	12.25	2.5
Cholera	10.50	2.3
Covid-19	10.50	2.5
Crimean-congo-haemorrhagic-fever	9.00	1.5
Yellow-Fever	9.00	2.4
unknown-agent	9.00	1.3
Marburg	9.00	1.6
Neisseria-Meningitis	9.00	2.3
Measles	8.75	2.6
Lassa-fever	7.50	1.7
Rift-valley-fever	7.50	1.7
Dengue-fever	7.50	1.6
Polio-virus	7.50	2.4
Rabies	7.50	2.0
Monkeypox	6.25	1.6
Anthrax	6.25	1.6
Plague	6.25	1.4
Chikungunya	5.00	1.6


Africa CDC, 2024

Outbreaks are becoming more frequent and severe, especially in settings with multiple converging risks



Strengthening health systems for epidemic and pandemic preparedness

- Surveillance & research
- National capacities
- Governance, coordination & financing
- **Equitable supply of medical countermeasures**




- Vaccines are cost-effective, preventing disruptions from outbreaks
- Vaccines available for ~20 life-threatening diseases (WHO, 2024)
- Success story: 150+ million lives saved in 50 years of routine immunization (GAVI, 2024)
- COVID-19: 20 million lives saved in the first year of use (Watson, 2022)
- **Extend benefits of vaccines to accelerate universal health coverage**

Unhealthy vaccine markets lead to insufficient and delayed access




Consequences of the vicious cycle:

- Unclear *current* and *future* market needs
- Low market attractiveness (few suppliers)
- Limited geographic diversification of production
- Delayed and unmet demand



Unhealthy vaccine markets lead to insufficient and delayed access



Turning a vicious cycle into a virtuous cycle: increased supply, lower cost, & more equitable access

Consequences of the vicious cycle:

- Unclear *current* and *future* market needs
- Low market attractiveness (few suppliers)
- Limited geographic diversification of production
- Delayed and unmet demand

Emergency vaccine stockpiles

- Managed by the International Coordinating Group on Vaccine Provision (WHO, UNICEF, IFRC, MSF)
- Meningitis (1997), Yellow Fever (2001), **Cholera** (2013), & **Ebola** (2021)
- For Cholera & Ebola, ~100% vaccines used are supplied from stockpiles

Cholera vaccine stocks 'empty' as cases surge

By Jennifer Rigby and Gloria Dickie
February 14, 2024 9:11 PM GMT+1 · Updated 8 days ago




The ICG Ebola vaccine stockpile reached the goal of 500,000 doses in 2022 and, as of December 2023, holds 518,890 doses. In total, **208,390 (40%) doses from the current stockpile are scheduled to expire in 2024.** Apr 25, 2024

National Institutes of Health (NIH) (.gov)
<https://pmc.ncbi.nlm.nih.gov/articles/PMC11065462>

Use of Ebola Vaccines — Worldwide, 2021–2023 - PMC

Outline



Pathogens with epidemic potential

- Priority lists
- Multi-dimensional risks
- Unhealthy vaccine markets

Systems analysis of global vaccine stockpiles


- Approach
- Drivers of behavior
- Case studies

Dynamic understanding of market health

- Conclusions
- Future work





Vaccine stockpiles serve as buffer mechanisms to overcome demand uncertainty



Project goal: Identify the underlying drivers of stockpile dynamics to inform their design

Methodology:



Considerations:

- Stockpile decisions depend on numerous, interacting processes and stakeholders
- Perishable inventory with intermittent demand
- Difficult to assess value – relative costs and benefits – over long time horizons

Growing unmet demand for oral cholera vaccines as outbreaks surge



Cholera now threatens 1bn people. It's time to finish what we began in the 19th century
Hakainde Hichilema and Tedros Adhanom Ghebreyesus

NEWS · Volume 5, Issue 7, P632, July 2024 · Open Access

New measures to tackle the global cholera surge

[Priya Venkatesan](#)

WORLD REPORT · Volume 403, Issue 10430, P891-892, March 09, 2024

The great cholera vaccine shortage

[Talha Burki](#)

News

Cholera: WHO rations vaccines to preserve stocks amid rising outbreaks

BMJ 2022 ; 379 doi: <https://doi.org/10.1136/bmj.o2528> (Published 21 October 2022)

Cite this as: BMJ 2022;379:o2528

Cholera vaccine stocks 'empty' as cases surge


By Jennifer Rigby and Gloria Dickie
February 14, 2024 9:11 PM GMT+1 · Updated 8 days ago



“Conflict, poverty, the climate crisis and global socioeconomic inequities are all underlying reasons why outbreaks tend to be larger and deadlier...”
– WHO, DG, 2024



Complexity emerges from asynchronous supply and demand dynamics, with competing feedback mechanisms



Replenishment dynamics:

Aim: reduce the stockpile gap

Core dynamics $r(t)$

- Number of suppliers
- Capacity allocation
- Scaling-up capacity
- Adjusting target stockpile level based on disease threat

Related mechanisms

- Programmatic funding
- Anticipating demand (forecasts)

Deployment dynamics:

Aim: improve health outcomes

Core dynamics dt


- Surveillance and non-pharmaceutical interventions
- Current and future disease risks
- Vaccination strategy and vaccine-induced immunity
- Health system capacity
- Community perceptions

Related mechanisms


- Growing evidence on vaccine effectiveness
- Political and financial support




Managing priority pathogens: contrasting examples of Cholera & Ebola




New outbreaks & corresponding CFR, Ebola Virus - Zaire (1976-2024)




Countries reporting cholera deaths (2023)




Policy aim for disease management



Vaccination strategy: global (SAGE) & national



Outline



Pathogens with epidemic potential

- Priority lists
- Multi-dimensional risks
- Unhealthy vaccine markets

Systems analysis of global vaccine stockpiles

- Approach
- Drivers of behavior
- Case studies

Dynamic understanding of market health

- Conclusions
- Future work




Dynamic stockpile behavior promotes continuous learning and system re-design

Stockpile performance serves as an indicator of market health

- Chronic stock-outs ~ scarcity of vaccine supply
- Chronic wastage ~ low visibility on vaccine demand, limited uptake
- Delayed order fulfillment ~ logistical, regulatory, and structural hurdles
- Capture how disease burden, vaccine demand, and supply evolve with time

The role of stockpiles adapts to meet shifting public health goals





Systems analysis provides a foundation for quantitative modeling and simulations



There is a need for models that better integrate vaccine supply and demand dynamics


- Requires active and frequent engagement stakeholders across disciplines/sectors
- Builds on deep understanding of historical behavior for model validation
- Allows users to define and explore relevant scenarios and interventions

Baseline: assuming 500k stockpile, with a demand of 750k doses every 6 months




Leverage point: reducing replenishment time

Increasing production capacity




Leverage point: increasing buffer capacity


Increasing stockpile size



Reducing process time (product innovation)



Prioritizing orders (limit deployment)





1:45–3:45 pm

Live French translation is available. Un interprète est disponible..

Friday 15, Nov 2024

**WORKSHOP:
Systems Thinking –
applied to Mpox
and other public
health emergencies**

Location:
Meeting Room 1

Background: This workshop invites participants to apply various systems thinking tools to outbreak response and preparedness in Africa. In particular, the workshop focuses on Mpox (which has spread to 15+ African countries in 2024) and other priority pathogens with epidemic potential, including Ebola and Marburg. Sporadic outbreaks present a unique challenge for supply chains, as they are inherently difficult to anticipate and plan for. Furthermore, they lead to wide-ranging disruptions, including to routine health services. Systems thinking tools are particularly useful to identify the root-cause(s) of behavior and unintended consequences of interventions. The participatory nature of this workshop, bringing numerous stakeholders together, will be an opportunity to share insights and broaden perspectives.

Workshop objectives:

- To collectively build systems diagrams that reveal factors driving the behavior (e.g., disease epidemiology, delayed access to countermeasures) observed in the ongoing Mpox outbreak
- To identify leverage points and interventions that can lead to system change in both the short-term (outbreak control) and long-term (prevention)
- To apply system archetypes to the management of sporadic outbreaks and foresight thinking to imagine the impact of Africa's New Public Health Order
- To foster collaboration and shared understanding among stakeholders

Session by: Access-To-Medicines (ATM) Research Centre, KU Leuven

